BIOTRONIK completes enrollment in Passeo-18 Lux DEB catheter clinical study for PAD

Posted on : 20 September 2011
BIOTRONIk announced the completion of enrollment in the BIOLUX P-I - a clinical study investigating the use of a drug-eluting balloon (DEB) catheter, a promising new approach to treating disease in the more challenging peripheral vascular anatomy. Read more

Biotronik Launches Passeo-18 Lux Drug-Releasing Balloon in Europe

Posted on : 22 January 2014
Biotronik (Lake Oswego, OR) announced the release of its Passeo-18 Lux drug-releasing balloon (DRB) in all countries recognizing CE Mark. The device recently earned European CE Mark approval. The company stated that the Passeo-18 Lux is a novel combination device for treating de novo and restenotic femoropopliteal lesions. The device?s design is based on the company?s Passeo-18 percutaneous transluminal angioplasty (PTA) catheter, which is coated with a matrix of antiproliferative paclitaxel and a biocompatible excipient that enables an optimal drug transfer to the target lesion tissue. The Passeo-18 Lux includes a novel protective insertion aid to facilitate easier device introduction and handling. Read more

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.